Differences in the management of inflammatory bowel disease in children and adolescents compared to adults

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease (IBD) Research
• Childhood and Adolescent Medicine

Background:

• Inflammatory Bowel Disease (IBD) presents unique challenges in pediatric populations, often with subtle signs and symptoms.
• Comprehensive management extends beyond intestinal symptoms to include growth, sexual maturation, extra-intestinal manifestations, and psychosocial well-being.

Purpose of the Study:

• To outline the distinct considerations for managing IBD in children and adolescents.
• To highlight the factors influencing drug selection and treatment strategies in pediatric IBD patients.

Main Methods:

• Review of current literature and clinical guidelines for pediatric IBD management.
• Analysis of age-specific treatment considerations, including drug efficacy, safety, and administration.

Main Results:

• Treatment strategies differ from adults due to dosing uncertainties, administration challenges (e.g., swallowing capsules), nutritional needs for growth, long-term safety data scarcity, corticosteroid side effects, and psychosocial impact.
• Sulfasalazine and mesalamine suit mild disease; corticosteroids are vital for moderate-to-severe cases. Antibiotics (metronidazole, ciprofloxacin) target perianal Crohn's disease (CD).
• Nutritional therapies (elemental/polymeric formulas) are key for remission and growth, while immunomodulators (azathioprine, 6-mercaptopurine) reduce steroid dependence and hospitalizations. Combination therapy is often recommended.

Conclusions:

• Pediatric IBD management necessitates a holistic approach, integrating medical, nutritional, and psychosocial support.
• Tailored therapeutic strategies, including combination therapies, are essential for optimizing outcomes and minimizing side effects in young patients with IBD.